Oragenics (OGEN) Total Current Liabilities (2010 - 2023)
Oragenics' (OGEN) quarterly Total Current Liabilities came in at $1.8 million in Q4 2023, up 12.65% YoY from $1.6 million in Q4 2022, and up 28.25% on a QoQ basis from $1.4 million in Q3 2023.
Oragenics (OGEN) Total Current Liabilities (2010 - 2023) Analysis & Trends
Oragenics (OGEN) has 14 years of Total Current Liabilities data on file, last reported at $1.8 million in Q4 2023.
- Quarterly Total Current Liabilities rose 12.65% year-over-year to $1.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.8 million (up 12.65% YoY) and the FY2023 annual result came in at $1.8 million, up 12.65% from the prior year.
- Total Current Liabilities climbed to $1.8 million in Q4 2023, from $1.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.2 million in Q3 2019 to a low of $868880.0 in Q1 2021.
- A 5-year average of $1.6 million and a median of $1.6 million in 2022 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 99.15% in 2021, down 57.1% in 2021.
- Tracing OGEN's Total Current Liabilities over 5 years: stood at $1.9 million in 2019, then retreated by 27.47% to $1.3 million in 2020, then gained by 7.68% to $1.4 million in 2021, then rose by 10.45% to $1.6 million in 2022, then rose by 12.65% to $1.8 million in 2023.
- The last three Total Current Liabilities figures came in at $1.8 million (Q4 2023), $1.4 million (Q3 2023), and $1.1 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 630.93 Mn |
| 10 | Oragenics | 2.36 Mn | 2.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.78 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 1.57 Mn |
| Jun 30, 2022 | 1.46 Mn |
| Mar 31, 2022 | 1.41 Mn |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 2.20 Mn |
| Jun 30, 2021 | 2.12 Mn |
| Mar 31, 2021 | 868,880.00 |
| Dec 31, 2020 | 1.34 Mn |
| Sep 30, 2020 | 1.10 Mn |
| Jun 30, 2020 | 1.36 Mn |
| Mar 31, 2020 | 2.03 Mn |
| Dec 31, 2019 | 1.85 Mn |
| Sep 30, 2019 | 2.25 Mn |
| Jun 30, 2019 | 1.89 Mn |
| Mar 31, 2019 | 2.19 Mn |